CardioVascular Disease Prevention. CVD prevention ‘The evidence that most cardiovascular disease is preventable continues to grow.’ ‘The evidence that.

Slides:



Advertisements
Similar presentations
New Insights about Beef and Heart Health February 2012.
Advertisements

Lipid Management in 2015: Risk & Controversies
The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Internal Medicine/Pediatrics.
CONTROLLING YOUR RISK FACTORS Taking the Steps to a Healthy Heart.
REVIEW OF AHA DIETARY GUIDELINES Nita Purcell, MS, RD, LD, CDE.
10 Points to Remember for the Management of Overweight and Obesity in Adults Management of Overweight and Obesity in Adults Summary Prepared by Elizabeth.
« Systematic Cerebrovascular and cOronary Risk Evaluation » Global Cerebrovascular Risk Assessment SCORE - Canada « Systematic Cerebrovascular and cOronary.
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:
CVD risk estimation and prevention: An overview of SIGN 97.
Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care
Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Understanding blood lipids and glucose How a Healthy Lifestyle can improve your numbers Susan Fullmer, PhD RD Associate Teaching Professor Nutrition, Dietetics,
LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle Changes (TLC) and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL)
LIFESTYLE MODIFICATIONS FOR PREVENTING HEART DISEASE [e.g. HEART ATTACKS] [ primary prevention of coronary artery disease ] DR S. SAHAI MD [Med.], DM [Card]
Do You Need to Lose Weight?
Cardiovascular Disease in Women Module VII: Evidence-Based Guidelines.
Metabolic Syndrome. America’s Health Status one-third of U.S. adults (35.7%) are obese. 17% (12.5 million) of children 2—19 years are obese. Top leading.
{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
Cardiac Rehabilitation Are you or someone you know missing the benefits of Cardiac Rehabilitation? July
Appendix: Clinical Guidelines VBWG. I Intervention is useful and effective III Intervention is not useful or effective and may be harmful A Data derived.
Arthur Stillman, M.D., Ph.D., PI Pamela Woodard, M.D., Study Co-chair Randomized Evaluation of Patients with Stable Angina Comparing Utilization of Diagnostic.
December Cardiac Rehabilitation Are you or someone you know missing the benefits of Cardiac Rehabilitation?
METABOLIC Syndrome: a Global Perspective
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
Chapter 10: Special Topics in Adults & Chronic Diseases: Nutrition and Public Health Judith Sharlin, PhD, RD.
LIFESTYLE INTERVENTION You CAN’T change where you came from…….. You CAN change where you are going……
Diet and Lifestyle Reccomendations American Heart Association.
CARDIOVASCULAR DISEASE The Nature of CVD Extent and Trend of CVD Risk factors Social determinants High Risk Groups.
A Coordinated Approach to Cardiovascular Care Sharon Levine MD Associate Executive Director The Permanente Medical Group Kaiser Permanente Bay Area Council.
Management of Chronic Stable Angina AIMGP Seminar Series Mirek Otremba 2007.
Basma Y. Kentab. Aggressive comprehensive risk factor management: Improves survival, Reduces recurrent events and Reduces need for interventional procedures,
Metabolic Syndrome Yusra Mir, MD Zunairah Syed, MD Harjagjit Maan, MD.
1 Hypertension Overview. 2 Leading Risks For Death (World Health Organization 2002) Cholesterol Alcohol HYPERTENSION Tobacco use Overweight.
Staying Healthy Kim F Gibson, MD, FACP NNMC Bethesda The Key to Your Heart.
Staying Healthy Kim F Gibson, MD, FACP NNMC Bethesda The Key to Your Heart.
CARDIOVASCULAR CARE of the OUTPATIENT Diane M. Enzweiler, MSN, ANP-BC St. Elizabeth Physicians: Heart and Vascular.
Investigations: Urine examination. Urine examination. Serum K. Serum K. Serum creatinine. Serum creatinine. Blood Sugar. Blood Sugar. Hb. Hb.
1 EFFECT STUDY 2 EFFECT STUDY  Set national cardiac care benchmarks for hospitals to work towards 
Myocardial Ischemia: Concepts in Management Topics in Clinical Medicine February 14, 2007.
METABOLIC SYNDROME From PubMed Health A service of the National Library of Medicine, National Institutes of Health. A.D.A.M. Medical Encyclopedia, Atlanta,
Risk of hypertension (HTN) and non-drug management Aliakbar Tavassoli.
Cardiac Rehabilitation 2011 Update for Primary Care Providers Douglass A Morrison, MD, PhD Cardiac Rehabilitation, Medical Director Yakima Regional and.
Heart failure: The national burden AHA. Heart disease and stroke statistics–2005 update. Koelling TM et al. Am Heart J. 2004;147:74-8. VBWG Affects 1 million.
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
New Guidelines for Myocardial Ischemia Management.
COMMON LIFESTYLE DISEASES: CHD EMS 355 By: Dr. Bushra Bilal.
Laboratory Testing For Cardiovascular Risk
Results of 12 month follow up in Tulppa outpatient rehabilitation program.
PUTTING PREVENTION FIRST Vascular Checks Dr Bill Kirkup Associate NHS Medical Director.
© Continuing Medical Implementation ® …...bridging the care gap Geriovascular Prevention Optimizing Prevention of Cardiovascular Disease in the Elderly.
Yusra Mir, MD Zunairah Syed, MD Harjagjit Maan, MD
Chapter 11 Diet and Health
Copyright © 2015 by the American Osteopathic Association.
Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals
Hypertension Hanna K. Al-Makhamreh, MD FACC Interventional Cardiology.
Cardiovascular System
Diabetes Health Status Report
Achieving the Clinical Potential of RAAS Blockade
Heart Health & Diabetes
Chapter 10 Diet and Health
Progress and Promise in RAAS Blockade
Section I: RAS manipulation C. Update on clinical trials in CAD
Diabetes Dr. J. Antony Gagnon, Pharm.D., CDE, CAE
1 Physical Activity, Health, and Chronic Disease chapter 1 chapter
RCHC’s Cardiovascular Health Initiative
Obesity Eppie Habashi.
Section 6: Update on lipid treatment guidelines
Many post-MI patients are not receiving optimal therapy
Presentation transcript:

CardioVascular Disease Prevention

CVD prevention ‘The evidence that most cardiovascular disease is preventable continues to grow.’ ‘The evidence that most cardiovascular disease is preventable continues to grow.’ ‘…the majority of the causes of cardiovascular disease are known and modifiable.’ ‘…the majority of the causes of cardiovascular disease are known and modifiable.’ (Circulation. 2002;106: )

Objectives Know the core components of a secondary prevention plan for patients with cardiovascular disease Know the core components of a secondary prevention plan for patients with cardiovascular disease Develop a clinician checklist for your Post-MI patient Develop a clinician checklist for your Post-MI patient

CVD Scope Accounts for 17 million annual deaths globally Accounts for 17 million annual deaths globally 80% of which in developed countries Leading cause of death in United States (452,327 deaths in the 2004) Leading cause of death in United States (452,327 deaths in the 2004) U.S. Annual cost > 300 billion U.S. Annual cost > 300 billion

Prevention concept Implies ability to evaluate risks, disease burden, and offer effective intervention Implies ability to evaluate risks, disease burden, and offer effective intervention

CVD Prevention model

Success? -- Yes! Age adjusted death rates specific to coronary artery disease have declined by approximately 50% from (men and women) Secondary prevention initiatives a major factor for this trend Remaining underutilization

Post-MI patient office care Core Components  Initial risk assessment  Pharmacologic therapy  Lifestyle changes & interventions  Psychosocial evaluation

Initial Risk Assessment Establish burden of disease Establish burden of disease Evaluate CVD risks Evaluate CVD risks

Disease burden Symptoms Symptoms –Active or recurrent cardiac ischemia Review of coronary interventions Review of coronary interventions –Angiography, PCI/stent, bypass Manifest morbidity Manifest morbidity –Angina –CHF / depressed LVEF –Dysrhythmia (atrial/ventricular)

Spectrum of disease Lower risk patient Asymptomatic Asymptomatic PCI – one stent PCI – one stent Normal LVEF Normal LVEF No dysrhythmia No dysrhythmia Higher risk patient Recurrent /persistent angina Recurrent /persistent angina Multivessel disease / bypass Multivessel disease / bypass LVEF < 40% (with or without CHF symptoms) LVEF < 40% (with or without CHF symptoms) Dysrhythmia Dysrhythmia

Higher risk patients Revascularization assessment Revascularization assessment More extensive medication therapy More extensive medication therapy Anticoagulation therapy Anticoagulation therapy Pacemaker / defibrillator Pacemaker / defibrillator Specialist management Specialist management

Define CVD risk factors Major Major Smoking Smoking HTN HTN DM DM High LDL High LDL Low HDL Low HDL Advanced age Advanced age Underlying Underlying Obesity Physical inactivity Diet Psych/socio economic FHx CKD Genetic / racial factors

May also consider Emerging risk factors Other lipid factors Other lipid factors –Triglycerides, apolipoprotein subfractions Insulin resistance Insulin resistance Prothrombotic Prothrombotic markers markers Proinflammatory Proinflammatory markers markers

Post-MI Prevention Plan Aggressive Reduction Modifiable CVD Risk Factors Aggressive Reduction Modifiable CVD Risk Factors –Blood Pressure –Lipids –Diabetes –Diet –Weight –Physical Activity –Tobacco Cessation Therapeutic goal to Slow, Stop, Reverse disease progression Therapeutic goal to Slow, Stop, Reverse disease progression

Post-MI patient office care Core Components  Initial risk assessment - Lower vs. higher risk patient - Defined individual CVD risks  Pharmacologic therapy  Lifestyle changes & interventions  Psychosocial evaluation

Pharmacologic Therapy Lipid lowering agent Antiplatelet Beta-blocker ACE-Inhibitor

Lipid Lowering Agents Statins Statins (Class 1, Level A) –Risk reductions > 20% across all endpoints (MI, Stroke, mortality, revascularization) –Start on all post-MI patient –Goal LDL < 70 with at least 30% reduction in pretreatment LDL

Lipid Lowering Agents Niacin & Fibrates (Class II, level B) Niacin & Fibrates (Class II, level B) –For TG 200 to 499 **(after LDL lowering therapy) –Non-HDL-C goal < 130 target ; < 100 reasonable –For TG >500 Fibrates or Niacin may be used before LDL lowering therapy Omega-3-Fatty acids (Class II, level B) Omega-3-Fatty acids (Class II, level B) –Alternative for TG lowering agent (2-4g/day)

Antiplatelet agents Aspirin (Class I, Level A) Aspirin (Class I, Level A) –10-40% risk reduction of recurrent MI, Stroke, or vascular death –Start and continue indefinitely in all patients post-MI/ACS –75mg daily lowest effective dose for CAD, 160mg daily for additional stroke prevention

Antiplatelet agents Clopidogrel Clopidogrel –Agent of choice in ASA allergy pts –In post-MI patients: Minimum 14 days all patients 12 months for post-PCI, stent (Class I, Level B) Long-term therapy (1 year) is reasonable in all post-MI patients (Class IIa, Level C)

Beta-Blockers Start and continue indefinitely in all patients s/p MI, ACS, LV dysfunction with or without heart failure symptoms (Class I, Level A) Start and continue indefinitely in all patients s/p MI, ACS, LV dysfunction with or without heart failure symptoms (Class I, Level A) –13-36% mortality risk reduction –Monitor for contraindications

ACE-Inhibitors Start and continue indefinitely in all post-MI patients with LVEF <40% and for those with HTN, DM, or CKD (Class I, Level A) Start and continue indefinitely in all post-MI patients with LVEF <40% and for those with HTN, DM, or CKD (Class I, Level A) –Mortality risk reductions up to 27% in this group Reasonable to start in lower risk post-MI patients (normal LVEF) (Class IIa, Level B) Reasonable to start in lower risk post-MI patients (normal LVEF) (Class IIa, Level B)

Other Agents – ARBs & Aldosterone blockers Angiotensin receptor blockers Angiotensin receptor blockers –For ACE-I intolerant patients s/p MI, HF, LVEF <40% (Class I, Level A) –For ACE-I intolerant patients with hypertension alone (Class I, Level B) –In combo with ACE-I in systolic HF patients (Class IIb, Level B)

Other Agents – ARBs & Aldosterone blockers Aldosterone blockers Aldosterone blockers –In post-MI patients without significant renal dysfunction/hyperkalemia (<5.0) who are already on therapeutic ACE-I, Beta-Blocker, have LVEF <40%, and have either HTN or DM (Class I, Level A)

Diabetes Medications Goal Goal –Tight glucose control –At minimum A1C less than 7%

Pharmacologic Checklist Post-MI Aspirin / Clopidogrel Aspirin / Clopidogrel Statin Statin Beta Blocker Beta Blocker ACE-I ACE-I Consider Consider ARB, Aldosterone blocker, warfarin in appropriate cases ARB, Aldosterone blocker, warfarin in appropriate cases

What about NSAID use? Acetametaphen, ASA, tramadol, narcotic analgesics (short term) Non COX-2 selective NSAIDS NSAIDs with some COX-2 activity COX-2 Selective NSAIDS All Level C evidence

Post-MI patient office care Core Components  Initial risk assessment - Lower vs. higher risk patient - Defined individual CVD risks  Pharmacologic therapy - Aspirin/Clopidogrel, Statin, B-Blocker, ACE-I  Lifestyle changes & interventions  Psychosocial evaluation

Lifestyle Changes & Interventions Tobacco cessation Tobacco cessation Healthy food choices Healthy food choices Weight control Weight control Physical activity Physical activity Maintain normal Maintain normal - BP - BMI - Lipid profile - Sugar control - Fitness level

Administration of lifestyle changes… AHA and AACVPR recommends formal cardiac rehabilitation programs for patients with cardiovascular disease (CAD, Post-MI, chronic CHF, etc...) AHA and AACVPR recommends formal cardiac rehabilitation programs for patients with cardiovascular disease (CAD, Post-MI, chronic CHF, etc...) AHA and AACVPR AHA and AACVPR

Tobacco cessation GOAL GOAL –complete cessation –no exposure to environmental smoke Utilize 5 ‘A’ tool Utilize 5 ‘A’ tool –Ask –Advise –Assess –Assist –Arrange f/u

Healthy Food Choices Goal – healthy eating pattern Goal – healthy eating pattern –Fruits, vegies, whole grains, low/non-fat dairy, fish, legumes, lean meats –Saturated fat < 10% total calories; cholesterol < 300mg / day –Limit salt < 6g / day –Limit Etoh to < 2 drinks / day (men) < 1 drink /day (women) < 1 drink /day (women)

Diet tools/resources 5 ‘A’ approach still applies 5 ‘A’ approach still applies Nutritional consult Nutritional consult Website for self-help & education Website for self-help & education Website

Weight Control Goal Goal –Achieve & maintain BMI 18.5 to 24.9 kg/m2 –Waist circumference < 40 inches (men) < 35 inches (women) < 35 inches (women) Weight-management program Weight-management program –Caloric restriction & increased expenditure –If obese reduce weight by 10% in 1 st year 5 ‘A’ approach still applies 5 ‘A’ approach still applies

Physical Activity Goal Goal –30 min moderate intensity (40%-60% max HR) on most (preferably all) days of the week Additional benefit from vigorous intensity exercise (>60%max HR) Additional benefit from vigorous intensity exercise (>60%max HR) In sedentary, older, or patients with higher cardiac risk consider ETT In sedentary, older, or patients with higher cardiac risk consider ETT

Changing behaviors Principles Principles –Simplify & tailor behavioral change prescription –Ask about behavior at every visit –Involve family/social support in change process –Provide useful & appropriate information

Changing behaviors Tools/strategies –Organize support –Group programs –5 ‘A’ approach –Individual CBT –Goal setting / self- efficacy training

Post-MI patient office care Core Components  Initial risk assessment - Lower vs. higher risk patient - Defined individual CVD risks  Pharmacologic therapy - Aspirin/Clopidogrel, Statin, B-Blocker, ACE-I  Lifestyle changes & interventions - Tob cessation, Diet, Weight, Exercise  Psychosocial evaluation

Psychosocial Evaluation Psychosocial status should be evaluated specifically for symptoms of depression, anxiety, or sleep disorder along with social support assessment (AHA Class I, Level C) Psychosocial status should be evaluated specifically for symptoms of depression, anxiety, or sleep disorder along with social support assessment (AHA Class I, Level C) Treatment with CBT and SSRI is useful in patient with depression occurring up to a year after discharge (AHA Class IIa, Level C) Treatment with CBT and SSRI is useful in patient with depression occurring up to a year after discharge (AHA Class IIa, Level C)

Depression - Post-MI Associated with increased mortality rates Associated with increased mortality rates Treatment with SSRI have been shown to provide mortality benefit Treatment with SSRI have been shown to provide mortality benefit

Post-MI patient office care Core Components  Initial risk assessment - Lower vs. higher risk patient - Defined individual CVD risks  Pharmacologic therapy - Aspirin/Clopidogrel, Statin, B-Blocker, ACE-I  Lifestyle changes & interventions - Tob cessation, Diet, Weight, Exercise  Psychosocial evaluation - Depression screen (SSRI), social support

Summary ‘Health professionals should include prevention of CVD as an integral part of their daily clinical practice.’ –World Heart Federation, World Heart and Stroke Forum (Circulation 2004; 109; )

Go Save a heart